SCHEDULE: Enveric Biosciences Sees New 5.01% Stake by Braeden Lichti

Braeden Lichti and Northstrive Fund II LP have disclosed a combined beneficial ownership of 5.01% in Enveric Biosciences, Inc. common stock.

Summary

• Braeden Lichti and Northstrive Fund II LP have reported beneficial ownership of Enveric Biosciences, Inc. common stock.
• As of December 3, 2025, Braeden Lichti beneficially owns 29,920 shares, representing 5.01% of the class.
• Northstrive Fund II LP beneficially owns 25,915 shares, representing 4.34% of the class.
• The percentages are based on 596,978 shares outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed on November 14, 2025.
• Braeden Lichti is the Manager of Northstrive Fund II LP and may be deemed to beneficially own the securities held by the fund, though he disclaims beneficial ownership for all other purposes.

Sentiment

Score: 7

Explanation: The disclosure of a new significant beneficial ownership stake by an individual and an investment fund is generally viewed positively as it indicates investor confidence and potential future engagement, even if it's a passive investment.

Positives

• A new significant beneficial ownership stake of over 5% has been disclosed, potentially signaling confidence in the company's future prospects.
• The filing indicates an active investor, Braeden Lichti, is taking a notable position in the company, which can be a positive signal to the market.

Risks

• No specific risks related to Enveric Biosciences, Inc.'s operations or financial health are disclosed in this ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Enveric Biosciences, Inc. regarding its future operations or financial performance.

Management Comments

• Mr. Lichti disclaims beneficial ownership of these securities for all other purposes.

Industry Context

The disclosure of a new significant ownership stake in Enveric Biosciences by an individual and an investment fund suggests increased investor interest in the biotechnology sector, particularly in companies like Enveric. Such filings can sometimes precede further strategic involvement or indicate a belief in the company's long-term potential within its competitive landscape.

Comparison to Industry Standards

• This filing primarily concerns beneficial ownership disclosure rather than operational or financial results, therefore direct comparison to industry-specific performance benchmarks or comparable companies' project results is not applicable. The significance lies in the establishment of a new substantial shareholder.

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor could be seen as a positive signal, potentially increasing confidence and attracting further investment.
• Management: Awareness of a new substantial shareholder may influence strategic decisions or communication.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for Enveric Biosciences, Inc. or the reporting persons beyond the ownership disclosure itself.

Key Dates

Recommendation

The filing indicates a new significant beneficial ownership stake, which is generally a positive signal of investor confidence. However, as a Schedule 13G, it does not provide operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. It simply signals a notable investor has taken a position. Without further information on the company's fundamentals or the investor's intentions, a 'hold' recommendation is prudent, acknowledging the positive signal while awaiting more comprehensive data.

Keywords

Enveric Biosciences, EVBC, Schedule 13G, beneficial ownership, Braeden Lichti, Northstrive Fund II LP, institutional investment, common stock, SEC filing, biotechnology